المؤلفون: Patauner, F., Gallo, R., Durante-Mangoni, E., Bertolino, L.

المصدر: European Journal of Internal Medicine ; volume 122, page 35-37 ; ISSN 0953-6205

مصطلحات موضوعية: Internal Medicine

الإتاحة: https://doi.org/10.1016/j.ejim.2024.02.017Test
https://api.elsevier.com/content/article/PII:S0953620524000712?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0953620524000712?httpAccept=text/plainTest

المؤلفون: Karruli A., Migliaccio A., Pournaras S., Durante-Mangoni E., Zarrilli R.

المساهمون: Karruli, A., Migliaccio, A., Pournaras, S., Durante-Mangoni, E., Zarrilli, R.

مصطلحات موضوعية: antimicrobial susceptibility, antimicrobial therapy, carbapenem-resistant Acinetobacter baumannii, cefiderocol, mechanisms of resistance, sulbactam-durlobactam

الوصف: Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β-lactamase inhibitor combination, have been approved by the Food and Drug Administration for the treatment of A. baumannii infections. In this review, we discuss the mechanisms of action of and resistance to cefiderocol and sulbactam-durlobactam, the antimicrobial susceptibility of A. baumannii isolates to these drugs, as well as the clinical effectiveness of cefiderocol and sulbactam/durlobactam-based regimens against CRAB. Overall, cefiderocol and sulbactam-durlobactam show an excellent antimicrobial activity against CRAB. The review of clinical studies evaluating the efficacy of cefiderocol therapy against CRAB indicates it is non-inferior to colistin/other treatments for CRAB infections, with a better safety profile. Combination treatment is not associated with improved outcomes compared to monotherapy. Higher mortality rates are often associated with prior patient comorbidities and the severity of the underlying infection. Regarding sulbactam-durlobactam, current data from the pivotal clinical trial and case reports suggest this antibiotic combination could be a valuable option in critically ill patients affected by CRAB infections, in particular where no other antibiotic appears to be effective.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:001132234100001; volume:12; issue:12; firstpage:1; lastpage:19; numberofpages:19; journal:ANTIBIOTICS; https://hdl.handle.net/11588/950082Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85180439634

الإتاحة: https://doi.org/10.3390/antibiotics12121729Test
https://hdl.handle.net/11588/950082Test

المؤلفون: Kristoffersson, Anders N., 1985, Rognås, Viktor, Brill, Margreke JE, Dishon-Benattar, Y, Durante-Mangoni, E, Daitch, V, Skiada, A, Lellouche, J, Nutman, A, Kotsaki, A, Andini, R, Eliakim-Raz, N, Bitterman, R, Antoniadou, A, Karlsson, M O, Theuretzbacher, U, Leibovici, L, Daikos, G L, Mouton, J W, Carmeli, Y, Paul, M, Friberg, Lena E.

المصدر: Clinical Microbiology and Infection. 26(12):1644-1650

مصطلحات موضوعية: Carbapenem resistance, Colistin, Population pharmacokinetics, Renal function, Survival, Survival analysis

الوصف: OBJECTIVES: The aim was to analyse the population pharmacokinetics of colistin and to explore the relationship between colistin exposure and time to death.METHODS: Patients included in the AIDA randomized controlled trial were treated with colistin for severe infections caused by carbapenem-resistant Gram-negative bacteria. All subjects received a 9 million units (MU) loading dose, followed by a 4.5 MU twice daily maintenance dose, with dose reduction if creatinine clearance (CrCL) < 50 mL/min. Individual colistin exposures were estimated from the developed population pharmacokinetic model and an optimized two-sample per patient sampling design. Time to death was evaluated in a parametric survival analysis.RESULTS: Out of 406 randomized patients, 349 contributed pharmacokinetic data. The median (90% range) colistin plasma concentration was 0.44 (0.14-1.59) mg/L at 15 minutes after the end of first infusion. In samples drawn 10 hr after a maintenance dose, concentrations were >2 mg/L in 94% (195/208) and 44% (38/87) of patients with CrCL ≤120 mL/min, and >120 mL/min, respectively. Colistin methanesulfonate sodium (CMS) and colistin clearances were strongly dependent on CrCL. High colistin exposure to MIC ratio was associated with increased hazard of death in the multivariate analysis (adjusted hazard ratio (95% CI): 1.07 (1.03-1.12)). Other significant predictors included SOFA score at baseline (HR 1.24 (1.19-1.30) per score increase), age and Acinetobacter or Pseudomonas as index pathogen.DISCUSSION: The population pharmacokinetic model predicted that >90% of the patients had colistin concentrations >2 mg/L at steady state, but only 66% at 4 hr after start of treatment. High colistin exposure was associated with poor kidney function, and was not related to a prolonged survival.

وصف الملف: electronic

الوصول الحر: https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-429140Test
https://doi.org/10.1016/j.cmi.2020.03.016Test
https://uu.diva-portal.org/smash/get/diva2:1511731/FULLTEXT01.pdfTest

المؤلفون: Pascale, R., Toschi, A., Aslan, A.T., Massaro, G., Maccaro, A., Fabbricatore, D., Dell'Aquila, A., Ripa, M., Işık, M.E., Kızmaz, Y.U., Iacopino, S., Camici, M., Perna, F., Akinosoglou, K., Karruli, A., Papadimitriou-Olivgeris, M., Kayaaslan, B., Bilir, Y.A., Evren Özcan, E., Turan, O.E., Işık, M.C., Pérez-Rodríguez, M.T., Yagüe, B.L., Quirós, A.M., Yılmaz, M., Petersdorf, S., De Potter, T., Durante-Mangoni, E., Akova, M., Curnis, A., Gibertoni, D., Diemberger, I., Scudeller, L., Viale, P., Giannella, M.

المساهمون: CarDINe Study Group, Caroccia, N., Fanì, F., Arbizzani, F., Ramanathan, R., Scarpellini, P., Marzi, A., Mazzone, P., Placentino, F., Sammarini, G., Tenti, E., Leventopulos, G., Domenichini, G., Şahin, M., Suárez-Varela, M., Villegas, E.G.

المصدر: International journal of antimicrobial agents, vol. 61, no. 3, pp. 106734

مصطلحات موضوعية: Humans, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography/adverse effects, Positron Emission Tomography Computed Tomography/methods, Defibrillators, Implantable/adverse effects, Implantable/microbiology, Retrospective Studies, Radiopharmaceuticals, Risk Factors, Cardiovascular Infections, Gram-Negative Bacterial Infections/epidemiology, Gram-Negative Bacterial Infections/complications, Obesity, Prosthesis-Related Infections/epidemiology, Prosthesis-Related Infections/diagnosis, CIED infection, Cardiovascular implantable electronic devices, Endocarditis, FDG PET/CT, Gram-negative

الوصف: Infections of cardiovascular implantable electronic devices (CIED) are mainly due to Gram-positive bacteria (GPB). Data about Gram-negative bacteria CIED (GNB-CIED) infections are limited. This study aimed to investigate risk factors, clinical and diagnostic characteristics, and outcome of patients with GNB-CIED. A multicentre, international, retrospective, case-control-control study was performed on patients undergoing CIED implantation from 2015 to 2019 in 17 centres across Europe. For each patient diagnosed with GNB-CIED, one matching control with GPB-CIED infection and two matching controls without infection were selected. A total of 236 patients were enrolled: 59 with GNB-CIED infection, 59 with GPB-CIED infection and 118 without infection. No between-group differences were found regarding clinical presentation, diagnostic and therapeutic management. A trend toward a higher rate of fluorodeoxyglucose positron emission computed tomography (FDG PET/CT) positivity was observed among patients with GNB than in those with GPB-CIED infection (85.7% vs. 66.7%; P = 0.208). Risk factors for GNB-CIED infection were Charlson Comorbidity Index Score (relative risk reduction, RRR = 1.211; P = 0.011), obesity (RRR = 5.122; P = 0.008), ventricular-pacing ventricular-sensing inhibited-response pacemaker implantation (RRR = 3.027; P = 0.006) and right subclavian vein site of implantation (RRR = 5.014; P = 0.004). At 180-day survival analysis, GNB-CIED infection was associated with increased mortality risk (HR = 1.842; P = 0.067). Obesity, high number of comorbidities and right subclavian vein implantation site were associated with increased risk of GNB-CIED infection. A prompt therapeutic intervention that may be guided using FDG PET/CT is suggested in patients with GNB-CIED infection, considering the poorer outcome observed in this group.

وصف الملف: application/pdf

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36690123; info:eu-repo/semantics/altIdentifier/eissn/1872-7913; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_931BAB18E7639; https://serval.unil.ch/notice/serval:BIB_931BAB18E763Test; urn:issn:0924-8579; https://serval.unil.ch/resource/serval:BIB_931BAB18E763.P001/REF.pdfTest; http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_931BAB18E7639Test

الإتاحة: https://doi.org/10.1016/j.ijantimicag.2023.106734Test
https://serval.unil.ch/notice/serval:BIB_931BAB18E763Test
https://serval.unil.ch/resource/serval:BIB_931BAB18E763.P001/REF.pdfTest
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_931BAB18E7639Test

المؤلفون: Varon B., Palacios-Baena Z. R., de Kraker M. E. A., Rodriguez-Bano J., Leibovici L., Paul M., Bonten M., Carmeli Y., Carrara E., Chambers H. F., Davis J. S., Daikos G. L., de Kraker M., Durante-Mangoni E., Huttner A., Kalil A. C., Kaye K., Lee T. C., Paterson D., Gentil P. R., Bano J. R., Scudeller L., Tacconelli E., Thwaites G., Tong S., Yahav D.

المساهمون: Varon, B., Palacios-Baena, Z. R., de Kraker, M. E. A., Rodriguez-Bano, J., Leibovici, L., Paul, M., Bonten, M., Carmeli, Y., Carrara, E., Chambers, H. F., Davis, J. S., Daikos, G. L., de Kraker, M., Durante-Mangoni, E., Huttner, A., Kalil, A. C., Kaye, K., Lee, T. C., Paterson, D., Gentil, P. R., Bano, J. R., Scudeller, L., Tacconelli, E., Thwaites, G., Tong, S., Yahav, D.

مصطلحات موضوعية: Bloodstream infection, Cohort studie, Methodology, Mortality, Risk factor, Sepsis

الوصف: Background: Significant variations in the variables collected in clinical studies focusing on bacteraemia lead to inconsistency in the evaluation of risk factors for mortality. Objective: We aimed to define a minimum set of risk factors that should be assessed and reported in all studies assessing survival in bacteraemia. Study eligibility: We conducted a systematic review including observational prospective and retrospective cohort studies that assessed all-cause mortality among patients with bacteraemia. We included only studies computing an adjusted analysis for mortality, with >500 participants. Exposures: Independently significant risk factors for all-cause, preferably 30-day, mortality. Data sources: PubMed was used to identify eligible studies published between 2000 and 2020. A Delphi survey among experts was used to evaluate and prioritize the factors identified by the systematic review. Risk of bias: SIGN checklist complemented by risk of bias assessment of the adjusted analysis. Data synthesis: Definite universal risk factors were defined as those assessed in >50% of all included studies and significant in >50% of those. Potential universal risk factors were defined as those significant in >50% of studies evaluating the factor and a subgroup analysis was performed for studies of Staphylococcus aureus bacteraemia. Results: We included in the systematic review 62 studies, comprising more than 300,000 patients, from which a list of 17 risk factors was derived, whose association with all-cause mortality was statistically significant in most studies. The factors address baseline patient variables, the setting of infection acquisition, factors associated with the specific infection, the inflammatory response at onset of sepsis and management parameters where relevant. There were 14 risk factors for S. aureus bacteraemia. Conclusion: We identified a minimum set of universal factors to be collected, reported, and assessed, in all future studies evaluating factors associated with mortality in ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38182050; journal:CLINICAL MICROBIOLOGY AND INFECTION; https://hdl.handle.net/11591/518874Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85183643270

الإتاحة: https://doi.org/10.1016/j.cmi.2023.12.030Test
https://hdl.handle.net/11591/518874Test

المؤلفون: Patauner F., Durante-Mangoni E.

المساهمون: Patauner, F., Durante-Mangoni, E.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38036218; volume:30; issue:2; firstpage:155; lastpage:158; numberofpages:4; journal:CLINICAL MICROBIOLOGY AND INFECTION; https://hdl.handle.net/11591/518873Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85180320735

الإتاحة: https://doi.org/10.1016/j.cmi.2023.11.012Test
https://hdl.handle.net/11591/518873Test

المؤلفون: Ambrosioni, J., Hernandez-Meneses, M., Durante-Mangoni, E., Tattevin, P., Olaison, Lars, 1949, Freiberger, T., Hurley, J., Hannan, M. M., Chu, V. V., Hoen, B., Moreno, A., Cuervo, G., Llopis, J., Miro, J. M.

المصدر: Infectious Diseases and Therapy. 12(4):1083-1101

مصطلحات موضوعية: Infectious Medicine, Infektionsmedicin, Infective endocarditis, Europe, Epidemiology, Cardiac surgery, Mortality, clinical presentation, early surgery, diagnosis, mortality, etiology, impact, Infectious Diseases

الوصف: Introduction Infective endocarditis (IE) has undergone important changes in its epidemiology worldwide.Methods The study aimed to compare IE epidemiological features and outcomes according to predefined European regions and between two different time periods in the twenty-first century.Results IE cases from 13 European countries were included. Two periods were considered: 2000-2006 and 2008-2012. Two European regions were considered, according to the United Nations geoscheme for Europe: Southern (SE) and Northern-Central Europe (NCE). Comparisons were performed between regions and periods. A total of 4195 episodes of IE were included, 2113 from SE and 2082 from NCE; 2787 cases were included between 2000 and 2006 and 1408 between 2008 and 2012. Median (IQR) age was 63.7 (49-74) years and 69.4% were males. Native valve IE (NVE), prosthetic valve IE (PVE), and device-related IE were diagnosed in 68.3%, 23.9%, and 7.8% of cases, respectively; 52% underwent surgery and 19.3% died during hospitalization. NVE was more prevalent in NCE, whereas device-related IE was more frequent in SE. Higher age, acute presentation, hemodialysis, cancer, and diabetes mellitus all were more prevalent in the second period. NVE decreased and PVE and device-related IE both increased in the second period. Surgical treatment also increased from 48.7% to 58.4% (p < 0.01). In-hospital and 6-month mortality rates were comparable between regions and significantly decreased in the second period.Conclusions Despite an increased complexity of IE cases, prognosis improved in recent years with a significant decrease in 6-month mortality. Outcome did not differ according to the European region (SE versus NCE).

الوصول الحر: https://gup.ub.gu.se/publication/325349Test

المؤلفون: Reyes L. F., Murthy S., Garcia-Gallo E., Merson L., Ibanez-Prada E. D., Rello J., Fuentes Y. V., Martin-Loeches I., Bozza F., Duque S., Taccone F. S., Fowler R. A., Kartsonaki C., Goncalves B. P., Citarella B. W., Aryal D., Burhan E., Cummings M. J., Delmas C., Diaz R., Figueiredo-Mello C., Hashmi M., Panda P. K., Jimenez M. P., Rincon D. F. B., Thomson D., Nichol A., Marshall J. C., Olliaro P. L., Abbas A., Abdukahil S. A., Abe R., Abel L., Absil L., Acharya S., Acker A., Adriao D., Al Ageel S., Ahmed S., Ainscough K., Aisa T., Hssain A. A., Tamlihat Y. A., Akimoto T., Akmal E., Al Qasim E., Alalqam R., Al-dabbous T., Alegesan S., Alegre C., Alessi M., Alex B., Alexandre K., Al-Fares A., Alfoudri H., Ali I., Shah N. A., Alidjnou K. E., Aliudin J., Alkhafajee Q., Allavena C., Allou N., Altaf A., Alves J., Alves J. M., Alves R., Cabrita J. A., Amaral M., Ampaw P., Andini R., Andrejak C., Angheben A., Angoulvant F., Ansart S., Antonelli M., de Brito C. A. A., Apriyana A., Arabi Y., Aragao I., Araujo C., Arcadipane A., Archambault P., Arenz L., Arlet J. -B., Arnold-Day C., Arora L., Arora R., Artaud-Macari E., Asensio A., Asif N., Asim M., Assie J. B., Atique A., Attanyake A. M. U. L., Auchabie J., Aumaitre H., Auvet A., Azemar L., Azoulay C., Bach B., Bachelet D., Badr C., Baig N., Baillie J. K., Bak E., Bakakos A., Bal A., Balan V., Bani-Sadr F., Barbalho R., Barclay W. S., Barnikel M., Barrasa H., Barrelet A., Barrigoto C., Bartoli M., Baruch J., Basmaci R., Battaglini D., Bauer J., Dow D. B., Beane A., Bedossa A., Begum H., Behilill S., Beishuizen A., Beljantsev A., Bellemare D., Beltrame A., Beluze M., Benech N., Benkerrou D., Bennett S., Bento L., Berdal J. -E., Bergeaud D., Bergin H., Sobrino J. L. B., Bertoli G., Bertolino L., Bessis S., Bevilcaqua S., Bezulier K., Bhatt A., Bhavsar K., Bianco C., Singh M. B., Humaid F. B., Bissuel F., Bitker L., Bitton J., Blanco-Schweizer P., Blier C., Bloos F., Blot M., Boccia F., Bodenes L., Bogaert D., Boivin A. -H., Bolze P. -A., Bompart F., Borges D., Borie R., Bosse H. M., Botelho-Nevers E., Bouadma L., Bouchaud O., Bouchez S., Bouhmani D., Bouhour D., Bouiller K., Bouillet L., Bouisse C., Boureau A. -S., Bourke J., Bouscambert M., Bousquet A., Bouziotis J., Boxma B., Boyer-Besseyre M., Boylan M., Braconnier A., Braga C., Brandenburger T., Monteiro F. B., Brazzi L., Breen D., Breen P., Brickell K., Browne A., Browne S., Brusse-Keizer M., Buchtele N., Buesaquillo C., Bugaeva P., Buisson M., Burrell A., Bustos I. G., Butnaru D., Cabie A., Cabral S., Caceres E., Cadoz C., Garces R. C., Calligy K., Calvache J. A., Camoes J., Campana V., Campbell P., Canepa C., Cantero M., Caraux-Paz P., Carcel S., Cardellino C. S., Cardoso F., Cardoso N., Cardoso S., Carelli S., Carlier N., Carmoi T., Carney G., Carqueja I., Carret M. -C., Carrier F. M., Carroll I., Carson G., Casanova M. -L., Cascao M., Casey S., Casimiro J., Cassandra B., Castaneda S., Castanheira N., Castor-Alexandre G., Castrillon H., Castro I., Catarino A., Catherine F. -X., Cattaneo P., Cavalin R., Cavalli G. G., Cavayas A., Ceccato A., Cervantes-Gonzalez M., Chair A., Chakveatze C., Chan A., Chand M., Auger C. C., Chapplain J. -M., Chas J., Chaudry M., Iniguez J. S. C., Chen A., Chen Y. -S., Cheng M. P., Cheret A., Chiarabini T., Chica J., Chirouze C., Chiumello D., Cho S. -M., Cholley B., Chopin M. -C., Cidade J. P., Herreros J. M. C., Ciullo A., Clarke E., Clarke J., Clohisey S., Cobb P. J., Codan C., Cody C., Coelho A., Coles M., Colin G., Collins M., Colombo S. M., Combs P., Connor M., Conrad A., Contreras S., Conway E., Cooke G. S., Copland M., Cordel H., Corley A., Cornelis S., Cornet A. D., Corpuz A. J., Cortegiani A., Corvaisier G., Costigan E., Couffignal C., Couffin-Cadiergues S., Courtois R., Cousse S., Cregan R., Croonen S., Crowl G., Crump J., Cruz C., Bermudez J. L. C., Rojo J. C., Csete M., Cullen A., Curley G., Curlier E., Curran C., Custodio P., da Silva Filipe A., Da Silveira C., Dabaliz A. -A., Dagens A., Dahly D., Dalton H., Dalton J., Daly S., Damas J., Daneman N., Daniel C., Dankwa E. A., Dantas J., D'Aragon F., de Loughry G., de Mendoza D., De Montmollin E., de Oliveira Franca R. F., de Pinho Oliveira A. I., De Rosa R., de Silva T., de Vries P., Deacon J., Dean D., Debard A., Debray M. -P., DeCastro N., Dechert W., Deconninck L., Decours R., Defous E., Delacroix I., Delaveuve E., Delavigne K., Dell'Amore A., Delobel P., Delsing C., Demonchy E., Denis E., Deplanque D., Depuydt P., Descamps D., Desvallees M., Dewayanti S., Dhanger P., Diallo A., Diamantis S., Dias A., Diaz J. J., Diaz P., Didier K., Diehl J. -L., Dieperink W., Dimet J., Dinot V., Diop F., Diouf A., Dishon Y., Djossou F., Docherty A. B., Doherty H., Dondorp A. M., Donnelly C. A., Donnelly M., Donohue C., Donohue S., Donohue Y., Doran P., Dorival C., D'Ortenzio E., Douglas J. J., Dournon N., Downer T., Downey J., Downing M., Drake T., Driscoll A., Fonseca C. D., Dubee V., Dubos F., Ducancelle A., Dudman S., Dunand P., Dunning J., Duplaix M., Durante-Mangoni E., Durham L., Dussol B., Duthoit J., Duval X., Dyrhol-Riise A. M., Echeverria-Villalobos M., Egan S., Eira C., Sanharawi M. E., Elapavaluru S., Elharrar B., Ellerbroek J., Eloy P., Elshazly T., Enderle I., Endo T., Engelmann I., Enouf V., Epaulard O., Escher M., Esperatti M., Esperou H., Santo C. E., Esposito-Farese M., Estevao J., Etienne M., Ettalhaoui N., Everding A. G., Evers M., Fabre I., Fabre M., Faheem A., Fahy A., Fairfield C. J., Fakar Z., Fareed K., Faria P., Farooq A., Fatoni A. Z., Faure K., Favory R., Fayed M., Feely N., Feeney L., Fernandes J., Fernandes M. A., Fernandes S., Ferrand F. -X., Devouge E. F., Ferrao J., Ferraz M., Ferreira B., Ferreira I., Ferreira S., Ferrer-Roca R., Ferriere N., Ficko C., Fiorda J., Flament T., Flateau C., Fletcher T., Florio L. L., Flynn D., Foley C., Foley J., Fomin V., Fonseca T., Fontela P., Forsyth S., Foster D., Foti G., Fourn E., Fraher M., Franch-Llasat D., Fraser C., Fraser J. F., Freire M. V., Ribeiro A. F., French C., Friedrich C., Fry S., Fuentes N., Fukuda M., Argin G., Gaborieau V., Gaci R., Gagliardi M., Gagnard J. -C., Gagneux-Brunon A., Gaiao S., Skeie L. G., Gallagher P., Gamble C., Garan A., Garcia R., Barrio N. G., Garimella N., Garot D., Garrait V., Gauli B., Gault N., Gavin A., Gavrylov A., Gaymard A., Gebauer J., Geraud E., Morlaes L. G., Germano N., Ghosn J., Giani M., Gibson J., Gigante T., Gilg M., Gilroy E., Giordano G., Girvan M., Gissot V., Glikman D., Glybochko P., Gnall E., Goco G., Goehringer F., Goepel S., Goffard J. -C., Golob J., Gomez-Junyent J., Gominet M., Gonzalez A., Gordon P., Gorenne I., Goubert L., Goujard C., Goulenok T., Grable M., Graf J., Grandin E. W., Granier P., Grasselli G., Green C. A., Greene C., Greenhalf W., Greffe S., Grieco D. L., Griffee M., Griffiths F., Groenendijk A., Lordemann A. G., Gruner H., Gu Y., Guedj J., Guego M., Guellec D., Guerguerian A. -M., Guerreiro D., Guery R., Guillaumot A., Guilleminault L., de Castro M. G., Guimard T., Haalboom M., Haber D., Habraken H., Hachemi A., Hadri N., Haidri F., Hakak S., Hall A., Hall M., Halpin S., Hameed J., Hamer A., Hamidfar R., Hammond T., Haniffa R., Hardwick H., Harrison E. M., Harrison J., Harrison S. B. E., Hasan M. S., Hashmi J., Hayat M., Hayes A., Hays L., Heerman J., Heggelund L., Hendry R., Hennessy M., Hentzien M., Hershey A., Hesstvedt L., Hidayah A., Higgins D., Higgins E., Higgins R., Hinchion R., Hinton S., Hitoto H., Ho A., Hoctin A., Hoffmann I., Hoiting O., Holt R., Holter J. C., Horby P., Horcajada J. P., Hoshino K., Houas I., Hough C. L., Hsu J. M. -Y., Hulot J. -S., Huo S., Hurd A., Hussain I., Ijaz S., Ikram A., Illes H. -G., Imbert P., Imran M., Sikander R. I., Imtiaz A., Inacio H., Dominguez C. I., Ippolito M., Isgett S., Isidoro T., Isnard M., Ivulich D., Jaafar D., Jaafoura S., Jabot J., Jackson C., Jamieson N., Jaquet P., Jaud-Fischer C., Jaureguiberry S., Jego F., Jenum S., Garcia R. N. J., Joseph C., Joseph M., Joshi S., Jourdain M., Jouvet P., Jung A., Juzar D., Kafif O., Kaguelidou F., Kali S., Kalomoiri S., Kandamby D. H., Kandel C., Kanwal D., Kataria A., Katz K., Kay C., Keane H., Keating S., Kelly A., Kelly C., Kelly N., Kelly S., Kelly Y., Kelsey M., Kennon K., Kernan M., Kerroumi Y., Keshav S., Khalid I., Khalid O., Khalil A., Khan C., Khan I., Khan Q. A., Khanal S., Khatak A., Khawaja A., Kho M. E., Khoo S., Khoso N., Kida Y., Kiiza P., Granerud B. K., Kildal A. B., Kimmoun A., Kindgen-Milles D., Kitamura N., Klenerman P., Klont R., Bekken G. K., Knight S. R., Kobbe R., Kodippily C., Vasconcelos M. K., Koirala S., Kosgei C., Kpangon A., Krawczyk K., Kruglova O., Kumar D., Kumar M., Vijayaraghavan B. K. T., Vecham P. K., Kuriakose D., Kurtzman E., Kutsogiannis D., Kutsyna G., Kyriakoulis K., Lachatre M., Lacoste M., Laffey J. G., Lagrange M., Laine F., Lairez O., Lakhey S., Lalueza A., Lambert M., Lamontagne F., Langelot-Richard M., Langlois V., Lantang E. Y., Lanza M., Laouenan C., Laribi S., Lariviere D., Lasry S., Latif N., Launay O., Laureillard D., Lavie-Badie Y., Law A., Lawrence C., Lawrence T., Le M., Le Bihan C., Le Bris C., Le Falher G., Le Fevre L., Le Hingrat Q., Le Marechal M., Le Mestre S., Le Moal G., Le Moing V., Le Nagard H., Le Turnier P., Leal E., Santos M. L., Lee J., Lee S. H., Lee T. C., Leeming G., Lefebvre B., Lefebvre L., Lefevre B., LeGac S., Lelievre J. -D., Lellouche F., Lemaignen A., Lemee V., Lemeur A., Lemmink G., Lennon J., Leon R., Leone M., Lescure F. -X., Lesens O., Lesouhaitier M., Lester-Grant A., Levy B., Levy Y., Levy-Marchal C., Lewandowska K., L'Her E., Bassi G. L., Liaquat A., Liegeon G., Lim W. S., Lima C., Lina B., Lind A., Lingas G., Lion-Daolio S., Liu K., Livrozet M., Lizotte P., Loforte A., Lolong N., Lopes D., Loschner A. L., Loubet P., Loufti B., Louis G., Lourenco S., Lovelace-Macon L., Lowik M., Lucet J. C., Bermejo C. L., Luna C. M., Luong L., Luque N., Luton D., Lwin N., Lyons R., Maasikas O., Mabiala O., Machado M., Machado S., Macheda G., Madiha H., de la Calle G. M., Mahieu R., Mahy S., Maia A. R., Maier L. S., Maillet M., Maitre T., Malfertheiner M., Malik N., Mallon P., Maltez F., Malvy D., Manda V., Mandelbrot L., Mankikian J., Manning E., Manuel A., Sant C. M., Malaque A., Marino D., Marino F., Markowicz S., Marques A., Marquis C., Marsh B., Marsh L., Marshal M., Martelli C. T., Martin E., Martin-Blondel G., Martinot M., Martins A., Martins J., Martins N., Rego C. M., Martucci G., Martynenko O., Marwali E. M., Maslove D., Mason S., Masood S., Nor B. M., Matan M., Mathew M., Mathieu D., Mattei M., Matulevics R., Maulin L., Maxwell M., Maynar J., Mazzoni T., Mc Evoy N., Mc Sweeney L., McArthur C., McCarthy A., McCloskey C., McConnochie R., McDermott S., McDonald S. E., McElroy A., McElwee S., McEneany V., McGeer A., McKay C., McKeown J., McLean K. A., McNally P., McNicholas B., McPartlan E., Meaney E., Mear-Passard C., Mechlin M., Atif M., Meher M., Mele F., Melo L., Memon K., Mendes J. J., Menkiti O., Menon K., Mentre F., Mentzer A. J., Mercier E., Mercier N., Merckx A., Mergeay-Fabre M., Mergler B., Mesquita A., Metwally O., Meybeck A., Meyer D., Meynert A. M., Meysonnier V., Meziane A., Mezidi M., Michelanglei C., Michelet I., Mihnovit V., Moin A., Molina D., Molinos E., Molloy B., Mone M., Monteiro A., Montes C., Montrucchio G., Moore S., Moore S. C., Cely L. M., Moro L., Motherway C., Motos A., Mouquet H., Perrot C. M., Moyet J., Mufti A. K., Mullaert J., Muller F., Muller K. E., Munblit D., Muneeb S., Munir N., Murphy A., Murphy L., Murris M., Musaab H., Muvindi H., Myrodia D. M., Mohd-Hanafiah F. N., Nagpal D., Nagrebetsky A., Narayanan N., Khan R. N., Nazerali-Maitland A., Neant N., Nekliudov N., Neto R., Neumann E., Ng P. Y., Nghi A., Nguyen D., Choileain O. N., Leathlobhair N. N., Nitayavardhana P., Nonas S., Noret M., Norman L., Notari A., Noursadeghi M., Nowinski A., Nseir S., Nunez J. I., Nurnaningsih N., Nyamankolly E., Brien F. O., Callaghan A. O., O'Callaghan A., Occhipinti G., OConnor D., O'Donnell M., Ogston T., Ogura T., O'Halloran S., O'Hearn K., Oliveira J., Oliveira L., Ong D. S. Y., Oosthuyzen W., Opavsky A., Openshaw P., Orakzai S., Orozco-Chamorro C. M., Ortoleva J., Osatnik J., O'Shea L., O'Sullivan M., Ouamara N., Ouissa R., Oziol E., Pagadoy M., Pages J., Palacios A., Palacios M., Palmarini M., Panarello G., Paneru H., Panigada M., Pansu N., Papadopoulos A., Parke R., Parker M., Parra B., Pasha T., Pasquier J., Pastene B., Patauner F., Patrao L., Patricio P., Patrier J., Patterson L., Pattnaik R., Paul C., Paul M., Paulos J., Paxton W. A., Payen J. -F., Peelman F., Peiffer-Smadja N., Peigne V., Pejkovska M., Pelosi P., Peltan I. D., Pereira R., Perez D., Periel L., Perpoint T., Pesenti A., Pestre V., Petrou L., Petrovic M., Petrov-Sanchez V., Pettersen F. O., Peytavin G., Pharand S., Picard W., Picone O., Pierobon C., Piersma D., Pimentel C., Pinto R., Pires C., Pironneau I., Piroth L., Pius R., Plantier L., Poissy J., Pokeerbux R., Poli S., Pollakis G., Ponscarme D., Post A. -M., Postma D. F., Povoa P., Povoas D., Powis J., Prapa S., Preau S., Prebensen C., Preiser J. -C., Prinssen A., Pritchard M. G., Priyadarshani G. D. D., Proenca L., Pudota S., Puechal O., Semedi B. P., Pulicken M., Purcell G., Quesada L., Quinones-Cardona V., Gonzalez V. Q., Quist-Paulsen E., Quraishi M., Rabaud C., Rabindrarajan E., Rafael A., Rafiq M., Rahutullah A., Rainieri F., Ramachandran P., Ramakrishnan N., Ramalho J., Rammaert B., Ramos G. V., Rana A., Rangappa R., Ranjan R., Rapp C., Rashan A., Rashan T., Rasheed G., Rasmin M., Ratsep I., Rau C., Raza A., Real A., Rebaudet S., Redl S., Reeve B., Rehman A., Reid L., Reikvam D. H., Reis R., Remppis J., Remy M., Ren H., Renk H., Resseguier A. -S., Revest M., Rewa O., Reyes T., Ribeiro M. I., Richardson D., Richier L., Riera J., Rios A. L., Rishu A., Rispal P., Risso K., Rizer N., Robba C., Roberto A., Roberts S., Robertson D. L., Robineau O., Roche-Campo F., Rodari P., Rodeia S., Abreu J. R., Roessler B., Roger P. -M., Rojek A., Romaru J., Roncon-Albuquerque R., Roriz M., Rosa-Calatrava M., Rose M., Rosenberger D., Rossanese A., Rossetti M., Rossignol B., Rossignol P., Rousset S., Roy C., Roze B., Rusmawatiningtyas D., Russell C. D., Ryan M., Ryckaert S., Holten A. R., Saba I., Sadaf S., Sadat M., Sahraei V., Saidani N., Saint-Gilles M., Sakiyalak P., Salahuddin N., Salazar L., Saleem J., Sales G., Sallaberry S., Gandonniere C. S., Salvator H., Sanchez O., Sanchez-Miralles A., Sancho-Shimizu V., Sandhu G., Sandhu Z., Sandrine P. -F., Sandulescu O., Santos M., Sarfo-Mensah S., Banheiro B. S., Sarton B., Satyapriya S., Satyawati R., Saviciute E., Schaffer J., Schermer T., Scherpereel A., Schneider M., Schroll S., Schwameis M., Scott J. T., Scott-Brown J., Sedillot N., Seitz T., Selvanayagam J., Semaille C., Semple M. G., Senneville E., Sequeira F., Sequeira T., Neto A. S., Balazote P. S., Shadowitz E., Shamsah M., Sharjeel S., Sharma P., Shaw C. A., Shaw V., Sheharyar A., Shetty R. M., Shi H., Shiekh M., Shimizu K., Shrapnel S., Shrestha S. K., Shrestha P. S., Shum H. P., Mohammed N. S., Sibiude J., Siddiqui A., Sigfrid L., Sillaots P., Silva C., Silva M. J., Silva R., Sin W. C., Singh B. C., Singh P., Sitompul P. A., Skogen V., Smith S., Smood B., Smyth C., Smyth M., Snacken M., So D., Solomon J., Solomon T., Somers E., Sommet A., Song M. J., Song R., Song T., Chia J. S., Sotto A., Soum E., Sousa A. C., Sousa M., Uva M. S., Sperry A., Spinuzza E., Darshana B. P. S. R. S., Sriskandan S., Stabler S., Staudinger T., Stecher S. -S., Stienstra Y., Stiksrud B., Stolz E., Stone A., Streinu-Cercel A., Stuart A., Stuart D., Suen G., Suen J. Y., Sultana A., Summers C., Supic D., Surovcova M., Svistunov A., Syrigos K., Sztajnbok J., Szuldrzynski K., Tabrizi S., Tagherset L., Taleb S., Talsma J., Tampubolon M. L., Tanaka H., Taqdees H., Taqi A., Tardivon C., Tattevin P., Taufik M. A., Tawfik H., Tedder R. S., Teixeira J., Tejada S., Tellier M. -C., Teoule F., Terpstra P., Terrier O., Terzi N., Tessier-Grenier H., Tey A., Thakur A., Thibault V., Thiberville S. -D., Thill B., Thompson S., Thomson E. C., Thwaites R. S., Tierney P., Tieroshyn V., Timashev P. S., Timsit J. -F., Tissot N., Toki M., Tonby K., Torre M., Torres A., Torres M., Torres-Zevallos H., Towers M., Trapani T., Treoux T., Tromeur C., Trontzas I., Trouillon T., Truong J., Tual C., Tubiana S., Tuite H., Turmel J. -M., Turtle L. C. W., Twardowski P., Uchiyama M., Udayanga P. G. I., Udy A., Ullrich R., Uribe A., Usman A., Uyeki T. M., Vajdovics C., Val-Flores L., Valran A., Van de Velde S., van den Berge M., van der Palen J., van der Valk P., Van Der Vekens N., Van der Voort P., Van Der Werf S., van Gulik L., Van Hattem J., van Netten C., van Veen I., Vanel N., Vanoverschelde H., Varghese P., Vauchy C., Veislinger A., Vencken S., Ventura S., Verbon A., Vickers J., Vidal J. E., Vieira C., Vijayan D., Villanueva J. A., Villar J., Villeneuve P. -M., Villoldo A., Visseaux B., Visser H., Vitiello C., Vonkeman H., Vuotto F., Shukeri W. F. W. M., Wang C. -H., Webb S., Wei J., Weil K., Wesselius S., West T. E., Wham M., Whelan B., White N., Wicky P. H., Wiedemann A., Wijaya S. O., Wille K., Willems S., Williams V., Wils E. -J., Yiu N. W., Wong C., Xynogalas I., Yamazaki M., Yazdanpanah Y., Yelnik C., Yerkovich S., Yokoyama T., Yonis H., Yousif O., Yuliarto S., Zaaqoq A., Zabbe M., Zahran M., Zambon M., Zanella A., Zayyad H., Zoufaly A., Zucman D.

المساهمون: L.F. Reye, S. Murthy, E. Garcia-Gallo, L. Merson, E.D. Ibanez-Prada, J. Rello, Y.V. Fuente, I. Martin-Loeche, F. Bozza, S. Duque, F.S. Taccone, R.A. Fowler, C. Kartsonaki, B.P. Goncalve, B.W. Citarella, D. Aryal, E. Burhan, M.J. Cumming, C. Delma, R. Diaz, C. Figueiredo-Mello, M. Hashmi, P.K. Panda, M.P. Jimenez, D.F.B. Rincon, D. Thomson, A. Nichol, J.C. Marshall, P.L. Olliaro, A. Abba, S.A. Abdukahil, R. Abe, L. Abel, L. Absil, S. Acharya, A. Acker, D. Adriao, S. Al Ageel, S. Ahmed, K. Ainscough, T. Aisa, A.A. Hssain, Y.A. Tamlihat, T. Akimoto, E. Akmal, E. Al Qasim, R. Alalqam, T. Al-dabbou, S. Alegesan, C. Alegre, M. Alessi, B. Alex, K. Alexandre, A. Al-Fare, H. Alfoudri, I. Ali, N.A. Shah, K.E. Alidjnou, J. Aliudin, Q. Alkhafajee, C. Allavena, N. Allou, A. Altaf, J. Alve, J.M. Alve, R. Alve, J.A. Cabrita, M. Amaral, P. Ampaw, R. Andini, C. Andrejak, A. Angheben, F. Angoulvant, S. Ansart, M. Antonelli, C.A.A. de Brito, A. Apriyana, Y. Arabi, I. Aragao, C. Araujo, A. Arcadipane, P. Archambault, L. Arenz, J.-. Arlet, C. Arnold-Day, L. Arora, R. Arora, E. Artaud-Macari, A. Asensio, N. Asif, M. Asim, J.B. Assie, A. Atique, A.M.U.L. Attanyake, J. Auchabie, H. Aumaitre, A. Auvet, L. Azemar, C. Azoulay, B. Bach

مصطلحات موضوعية: COVID-19, Critical care, High flow nasal cannula, Invasive mechanical ventilation, Settore MED/41 - Anestesiologia

الوصف: Background: Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods: This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support. Results: A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83–7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97–2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36100904; info:eu-repo/semantics/altIdentifier/wos/WOS:000853343900001; volume:26; issue:1; firstpage:1; lastpage:16; numberofpages:16; journal:CRITICAL CARE; https://hdl.handle.net/2434/970978Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85137788209

الإتاحة: https://doi.org/10.1186/s13054-022-04155-1Test
https://hdl.handle.net/2434/970978Test

المؤلفون: Karruli A., de Cristofaro J., Andini R., Iossa D., Bernardo M., Amarelli C., Mattucci I., Zampino R., Zarrilli R., Durante-Mangoni E.

المساهمون: Karruli, A., de Cristofaro, J., Andini, R., Iossa, D., Bernardo, M., Amarelli, C., Mattucci, I., Zampino, R., Zarrilli, R., Durante-Mangoni, E.

مصطلحات موضوعية: Heart transplant, Hospitalization, Infection, MDR, Outcome, Risk factor, XDR

الوصف: (1) Background: The aim of this study was to assess risk factors for multidrug-resistant/ext-ensively drug-resistant (MDR/XDR) bacterial infections in heart transplant (HT) patients within three months after surgery and its impact on patient outcome. (2) Methods: Retrospective analysis of clinical, hemato-chemical, imaging, treatment and outcome data from 47 heart transplant recipients from January 2016 to December 2018. MDR/XDR infections were compared to non-MDR/XDR and noninfected patients. (3) Results: Most participants were males, median age 51 years: 35 (74.5%) developed an infection after HT; 14 (29.8%) were MDR/XDR infections. Prolonged hospital stay before HT correlated to MDR/XDR infection (p < 0.001). Sequential organ failure assessment (SOFA) score at sampling day was higher in MDR/XDR (p = 0.027). MDR/XDR were mostly blood-stream (BSI) (p = 0.043) and skin-soft tissue (SSTI) (p = 0.047) infections. Gram-negative infections were the most frequent, specifically carbapenem-resistant Klebsiella pneumoniae. Antibiotic therapy duration for MDR/XDR infections was longer (p = 0.057), eradication rate lower (p = 0.083) and hospital stay longer (p = 0.005) but not associated with a worse outcome. (4) Conclusions: MDR/XDR infections affect compromised HT recipients with a history of prolonged hospitalization, causing a lower rate of eradication and increased hospital stay. These frequently present as BSI and SSTI. We emphasize the need to prevent contamination of central venous catheters and the surgical site.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000666267000001; volume:9; issue:1210; firstpage:1; lastpage:13; numberofpages:13; journal:MICROORGANISMS; http://hdl.handle.net/11588/865346Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85107220352

الإتاحة: https://doi.org/10.3390/microorganisms9061210Test
http://hdl.handle.net/11588/865346Test

المؤلفون: Papst L., Beovic B., Pulcini C., Durante-Mangoni E., Rodriguez-Bano J., Kaye K. S., Daikos G. L., Raka L., Paul M., Abbo L., Abgueguen P., Almirante B., Azzini A. M., Bani-Sadr F., Bassetti M., Ben-Ami R., Beraud G., Botelho-Nevers E., Bou G., Boutoille D., Cabie A., Cacopardo B., Cascio A., Cassir N., Castelli F., Cecala M., Charmillon A., Chirouze C., Cisneros J. M., Colmenero J. D., Coppola N., Corcione S., Dalla Gasperina D., De la Calle Cabrera C., Delobel P., Di Caprio D., Durante Mangoni E., Dupon M., Ettahar N., Falagas M. E., Falcone M., Farinas M. C., Faure E., Forestier E., Foti G., Gallagher J., Gattuso G., Gendrin V., Gentile I., Giacobbe D. R., Gogos C. A., Grandiere Perez L., Hansmann Y., Horcajada J. P., Iacobello C., Jacob J. T., Justo J. A., Kerneis S., Komnos A., Kotnik Kevorkijan B., Lebeaux D., Le Berre R., Lechiche C., Le Moxing V., Lescure F. X., Libanore M., Martinot M., Merino de Lucas E., Mondain V., Mondello P., Montejo M., Mootien J., Munoz P., Nir-Paz R., Pan A., Pano-Pardo J. R., Patel G., Perez Rodriguez M. T., Piroth L., Pogue J., Potoski B. A., Pourcher V., Pyrpasopoulou A., Rahav G., Rizzi M., Salavert M., Scheetz M., Sims M., Spahija G., Stefani S., Stefos A., Tamma P. D., Tattevin P., Tedesco A., Torre-Cisneros J., Tripolitsioti P., Tsiodras S., Uomo G., Verdon R., Viale P., Vitrat V., Weinberger M., Wiener-Well Y.

المساهمون: Papst, L., Beovic, B., Pulcini, C., Durante-Mangoni, E., Rodriguez-Bano, J., Kaye, K. S., Daikos, G. L., Raka, L., Paul, M., Abbo, L., Abgueguen, P., Almirante, B., Azzini, A. M., Bani-Sadr, F., Bassetti, M., Ben-Ami, R., Beraud, G., Botelho-Nevers, E., Bou, G., Boutoille, D., Cabie, A., Cacopardo, B., Cascio, A., Cassir, N., Castelli, F., Cecala, M., Charmillon, A., Chirouze, C., Cisneros, J. M., Colmenero, J. D., Coppola, N., Corcione, S., Dalla Gasperina, D., De la Calle Cabrera, C., Delobel, P., Di Caprio, D., Durante Mangoni, E., Dupon, M., Ettahar, N., Falagas, M. E., Falcone, M., Farinas, M. C., Faure, E., Forestier, E., Foti, G., Gallagher, J., Gattuso, G., Gendrin, V., Gentile, I., Giacobbe, D. R., Gogos, C. A., Grandiere Perez, L., Hansmann, Y., Horcajada, J. P., Iacobello, C., Jacob, J. T., Justo, J. A., Kerneis, S., Komnos, A., Kotnik Kevorkijan, B., Lebeaux, D., Le Berre, R., Lechiche, C., Le Moxing, V., Lescure, F. X., Libanore, M., Martinot, M., Merino de Lucas, E., Mondain, V., Mondello, P., Montejo, M., Mootien, J., Munoz, P., Nir-Paz, R., Pan, A., Pano-Pardo, J. R., Patel, G., Perez Rodriguez, M. T., Piroth, L., Pogue, J., Potoski, B. A., Pourcher, V., Pyrpasopoulou, A., Rahav, G., Rizzi, M., Salavert, M., Scheetz, M., Sims, M., Spahija, G., Stefani, S., Stefos, A., Tamma, P. D., Tattevin, P., Tedesco, A., Torre-Cisneros, J., Tripolitsioti, P.

مصطلحات موضوعية: Acinetobacter baumannii, Carbapenem, Carbapenem-resistant Gram-negative bacilli, Combination therapy, Enterobacteriaceae, Polymyxin, Pseudomonas aeruginosa, Survey, Anti-Bacterial Agent, Cross Infection, Cross-Sectional Studie, Drug Resistance, Bacterial, Gram-Negative Bacteria, Gram-Negative Bacterial Infection, Hospital, Human, Microbial Sensitivity Test, Surveys and Questionnaires

الوصف: Objectives: To explore contemporary antibiotic management of infections caused by carbapenem-resistant Gram-negative bacteria in hospitals. Methods: Cross-sectional, internet-based questionnaire survey. We contacted representatives of all hospitals with more than 800 acute-care hospital beds in France, Greece, Israel, Italy, Kosovo, Slovenia, Spain and selected hospitals in the USA. We asked respondents to describe the most common actual practice at their hospital regarding management of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa through close-ended questions. Results: Between January and June 2017, 115 of 141 eligible hospitals participated (overall response rate 81.6%, country-specific rates 66.7%–100%). Most were tertiary-care (99/114, 86.8%), university-affiliated (110/115, 89.1%) hospitals and most representatives were infectious disease specialists (99/115, 86.1%). Combination therapy was prescribed in 114/115 (99.1%) hospitals at least occasionally. Respondents were more likely to consider combination therapy when treating bacteraemia, pneumonia and central nervous system infections and for Enterobacteriaceae, P. aeruginosa and A. baumannii similarly. Combination of a polymyxin with a carbapenem was used in most cases, whereas combinations of a polymyxin with tigecycline, an aminoglycoside, fosfomycin or rifampicin were also common. Monotherapy was used for treatment of complicated urinary tract infections, usually with an aminoglycoside or a polymyxin. The intended goal of combination therapy was to improve the effectiveness of the treatment and to prevent development of resistance. In general, respondents shared the misconception that combination therapy is supported by strong scientific evidence. Conclusions: Combination therapy was the preferred treatment strategy for infections caused by carbapenem-resistant Gram-negative bacteria among hospital representatives, even though high-quality evidence for carbapenem-based combination therapy is lacking.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29410094; info:eu-repo/semantics/altIdentifier/wos/WOS:000444923000011; volume:24 (10); firstpage:1070; lastpage:1076; numberofpages:7; journal:CLINICAL MICROBIOLOGY AND INFECTION; http://hdl.handle.net/11567/954120Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85043360070

الإتاحة: https://doi.org/10.1016/j.cmi.2018.01.015Test
http://hdl.handle.net/11567/954120Test